Spektrum der Augenheilkunde

, Volume 27, Issue 4, pp 181–183

Hyperhomocysteinämie bei Patienten/innen mit retinalen arteriellen Verschlüssen – gibt es Evidenz für einen Benefit einer therapeutischen Homocysteinsenkung?

  • Christoph Leisser
  • S. Christmann
  • A. Bodsch
  • N. Schrage
originalarbeit
  • 57 Downloads

Zusammenfassung

Hintergrund

Hyperhomocysteinämie, die bei mehr als 60 % der Patienten/innen vorliegt, zählt zu den unabhängigen Risikofaktoren bei retinalen Arterienverschlüssen.

Methode

120 Patienten/innen mit RAO wurden bezüglich Vorliegen einer Hyperhomocysteinämie ausgewertet und die aktuelle Literatur zur Homocysteinsenkung diskutiert.

Resultate

Eine Hyperhomocysteinämie von > 10 µmol/l lag bei 82,5 % und eine Hyperhomocysteinämie von > 15 µmol/l bei 44,3 % unserer Patienten/innen vor. Der mittlere Homocysteinplasmaspiegel war 15,5 µmol/l ± 6 µmol/l. Nebenbefundlich konnte bei 64,2 % eine arterielle Hypertonie, bei 55 % eine Hypercholesterinämie und bei 17,5 % ein Diabetes mellitus erhoben oder neu diagnostiziert werden.

Schlussfolgerung

Hyperhomocysteinämie zählt zu den häufigsten Comorbiditäten der retinalen arteriellen Verschlüsse, jedoch kann zum aktuellen Zeitpunkt eine Homocysteinsenkung bei Patienten/innen mit RAO bis zum Vorliegen von Studien, die einen Benefit zeigen, nicht routinemäßig empfohlen werden.

Schlüsselwörter

Hyperhomocysteinämie Retinale arterielle Verschlüsse Homocysteinsenkung 

Hyperhomocysteinemia and patients with retinal artery occlusions—Is there evidence for a benefit of homocysteine-lowering interventions?

Hyperhomocysteinemia and patients with retinal artery occlusions—is there evidence for a benefit of homocysteine-lowering interventions? Summary

Background

Hyperhomocysteinemia, affecting more than 60 % of patients with retinal artery occclusion, is an independent risk factor for that disease.

Methods

We evaluated plasma levels of homocysteine from 120 patients with retinal artery occlusion and discussed actual literature about homocysteine-lowering interventions.

Results

82.5 % of patients had hyperhomocysteinemia of > 10 µmol/l and 44.3 % hyperhomocysteinemia of > 15 µmol/l, with mean plasma levels of homocyste­ine of 15.5 µmol/l ± 6 µmol/l. Further results included 64.2 % of patients with arterial hypertension, 55 % with hypercholesterolemia and 17.5 % with diabetes mellitus.

Conclusion

Hyperhomocysteinemia is one of the most common comorbidities for retinal artery occlusion, but homocysteine-lowering interventions for patients with retinal artery occlusion should not be routinely recommended until studies showing a clear benefit for patients with retinal artery occlusions are available.

Keywords

Hyperhomocysteinemia Retinal artery occlusion Homocysteine-lowering interventions 

Literatur

  1. 1.
    Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, Weger M. DACH-LIGA Homocystein e.V. DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamines in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med. 2003;41(11):1392–403.PubMedGoogle Scholar
  2. 2.
    Pianka P, Almong Y, Man O, Goldstein M, Sela BA, Loewenstein A. Hyperhomocysteinaemia in patients with nonarteritic anterior ischemic optic neuropathy, central artery occlusion and retinal vein occlusion. Ophthalmology. 2000;107(8):1588–92.PubMedCrossRefGoogle Scholar
  3. 3.
    Weger M, Stanger O, Deutschmann H, Leitner HJ, Renner W, Schmut O, Semmelrock J, Haas A. The role of hyperhomocysteinemia and methylenetetrahydrofolate reductase (MTHFR) C677T mutation in patients with retinal artery occlusion. Am J Ophthalmol. 2002;134:57–61.PubMedCrossRefGoogle Scholar
  4. 4.
    Wong TY, Larsen EK, Klein R, Mitchell P, Couper DJ, Klein BE, Hubbard LD, Siscovick DS, Sharret AR. Cardiovascular risk factors for retinal vein occlusions and arteriolar emboli: the atherosclerosis risk in communities and Cardiovascular health studies. Ophthalmology. 2005;112(4):540–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Cugati S, Wang JJ, Rochtchina E, Mitchell P. Ten-year incidence of retinal emboli in an older population. Stroke. 2006;37(3):908–10.PubMedCrossRefGoogle Scholar
  6. 6.
    Chua B, Kifley A, Wong TY, Mitchell P. Homocysteine and retinal emboli: the blue mountains eye study. Am J Ophthalmol. 2006;142(2):322–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Cahill M, Karabatzaki M, Meleady R, Refsum H, Ueland P, Shields D, Mooney D, Graham I. Raised plasma homocysteine as a risk factor for retinal vacular occlusive disease. Br J Ophthalmol. 2000;84(2):154–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamine C therapy. Circulation. 1999;99(9):1156–60.PubMedCrossRefGoogle Scholar
  9. 9.
    Van den Berg M, Boers GH, Franken DG, Blom HJ, Van Kamp GJ, Jakobs C, Rauwerda JA, Kluft C, Stehouwert CD. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest. 1995;25(3):176–81.PubMedCrossRefGoogle Scholar
  10. 10.
    Sottilotta G, Oriana V, Latella C, Luise F, Piromalli A, Ramirez F, Mammi C, Occhiuto A, Lombardo VT. Role of hyperhomocystinemia in retinal vascular occlusive disease. Clin App Thromb Hemost. 2007;13(1):104–7.CrossRefGoogle Scholar
  11. 11.
    Marti-Carvajal AJ, Sola I, Lathyis D, Karakitsiou DE, Simancas-Racines D. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2013;1:CD006612Google Scholar
  12. 12.
    Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291(5):565–75.PubMedCrossRefGoogle Scholar
  13. 13.
    Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr. Herat Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354(15):1567–77.PubMedCrossRefGoogle Scholar
  14. 14.
    Loland KH, Bleie O, Blix AJ, Strand E, Ueland PM, Refsum H, Ebbing M, Nordrehaug JE, Nygard O. Effect of homocysteine-lowering B vitamin treatment on angiographic progression of coronary artery disease: a Western Norway B Vitamin Intervention Trial (WENBIT) substudy. Am J Cardiol. 2010;105(11):1577–84.PubMedCrossRefGoogle Scholar
  15. 15.
    Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354(15):1578–88.PubMedCrossRefGoogle Scholar
  16. 16.
    Christen WG, Glynn RJ, Chew EY, Albert CM, Manson JE. Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women’s Antioxidant and Folic Acid Cardiovascular Study. Arch Intern Med. 2009;169(4):335–41.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2013

Authors and Affiliations

  • Christoph Leisser
    • 1
  • S. Christmann
    • 1
  • A. Bodsch
    • 1
  • N. Schrage
    • 1
  1. 1.Augenklinik, Klinikum Köln MerheimKliniken der Stadt Köln gGmbHKölnDeutschland

Personalised recommendations